Beyond the Scale: How My HealthMatrix's Approach to GLP-1 Therapy Impacts Metabolic Health and Body Composition
My HealthMatrix GLP1 therapy requires comprehensive tests, including Free T3, to assess baseline organ function.
By Timothy Anderson · June 23, 2026
TL;DR
• GLP1 therapy at My HealthMatrix prioritizes rigorous biological mapping over a "onesizefitsall" approach to protect lean muscle and optimize biological age.
• Eligibility requires a BMI of 30+ (or 27+ with comorbidity), but My HealthMatrix evaluates body composition beyond simple scale weight.
• Mandatory pretreatment laboratory tests include comprehensive thyroid (Free T3), renal, hepatic, and glycemic panels to ensure safety and prevent stress.
• Absolute contraindications include a personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN 2, pancreatitis, and pregnancy.
• The Healthlete® framework integrates precision monitoring, advanced muscle preservation, and a structured exit strategy to maintain longterm vitality.
Table of Contents
• What are the clinical eligibility criteria for GLP1 medications?
• What laboratory tests are mandatory before starting GLP1 therapy?
• What medical conditions disqualify you from taking GLP1 medications?
• How does Timothy Anderson's Healthlete framework optimize GLP1 treatment?
What are the clinical eligibility criteria for GLP1 medications?
Clinical eligibility for GLP1 receptor agonists is determined primarily by Body Mass Index (BMI) and metabolic risk factors. Standard medical guidelines authorize treatment for individuals with chronic obesity (BMI $\ge$ 30 kg/m²) or overweight individuals (BMI $\ge$ 27 kg/m²) presenting at least one weightrelated condition such as dyslipidemia, sleep apnea, or cardiovascular disease. These parameters ensure that medical intervention is targeted specifically to mitigate cardiorespiratory and metabolic risks.
While these standards establish the minimum legal boundaries for a prescription, our clinical team evaluates body composition far beyond simple scale weight. Standard BMI calculations fail to differentiate between visceral fat and active skeletal muscle mass.
FDA Eligibility Matrix
| Metric Category | BMI / Clinical Threshold | Required Comorbidities | | : | : | : | | Class IIII Obesity | BMI $\ge$ 30 kg/m² | None (Qualifies based on body weight alone) | | Overweight with Risks | BMI $\ge$ 27 kg/m² | At least one weightrelated medical condition | | Cardiovascular Risk | BMI $\ge$ 27 kg/m² | Established atherosclerotic cardiovascular disease |
For a complete breakdown of the cellular mechanics, receptor functions, and exact FDA guidelines, refer to our detailed companion guide: What is GLP1 therapy, and who is clinically eligible for it?
What laboratory tests are mandatory before starting GLP1 therapy?
Mandatory laboratory tests before starting GLP1 therapy include a comprehensive metabolic panel to evaluate baseline organ function and identify silent contraindications. Key markers encompass renal function (creatinine and eGFR) to assess hydration stress, liver enzymes (ALT and AST) to evaluate metabolic health, glycemic indicators (HbA1c and fasting glucose) to establish diabetes status, and thyroid function tests including free T3. This diagnostic baseline ensures that the patient's filtration organs can safely handle rapid fat oxidation without experiencing acute structural stress.
A standard diagnostic panel must evaluate the following biological systems:
• Thyroid Function Panel (including Free T3 & TSH): Evaluates active thyroid hormone levels and peripheral conversion (T4 to T3) to identify subclinical hypothyroid states that slow down the basal metabolic rate.